

Technology Advisory Interests Register

Topic: Seladelpar for previously treated primary biliary cholangitis [ID6429]

Publication Date: 24 June 2026

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Matt Bradley	TAC Committee Member	Direct - financial	I hold shares in GSK who have recently published positive Phase 3 data for a potential new medicine called Linerixibat for the treatment of cholestatic pruritus (itch) associated with primary biliary cholangitis (PBC).	18/06/2025	It was agreed that Matt's declaration would prevent them from participating in discussions on this appraisal.
Simon McNamara	TAC Committee Member	Financial	GSK have a therapy (linerixibat) that is expected to receive regulatory approval for primary biliary cholangitis in 2026. It was announced recently that Alfasigma had acquired the rights to linerixibat from GSK. As part of this deal, GSK will receive future payment sales-related payments from Alfasigma (i.e., royalties and milestone payments). Given this, I am recusing myself from ID6429 to avoid any perception of bias.	15/04/2026	It was agreed that Simon's declaration would prevent them from participating in discussions on this appraisal.
Sital Shah	Expert	Direct - financial	Gilead – Speaker fees and educational grants, IPSEN - Speaker fees and educational grants.	03/02/2025	It was agreed that Sital's declaration would not prevent them from

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
					providing expert advice to the committee.
Dr Palak Trivedi	Expert	Direct - financial	I am director of PJT Medical Ltd., which provides advisory and consultancy services to the private sector with regards drug and device development (predominantly gastrointestinal and liver disease). This is not exclusive to Gilead.	11/12/2024 10/09/2025	It was agreed that Palak's declaration would not prevent them from providing expert advice to the committee.
Robert Mitchell - Thain	Expert	Direct - financial	The PBC Foundation has received funding from Gilead, but not within the last 12 months.	09/07/2025	It was agreed that Robert's declaration would not prevent them from providing expert advice to the committee.
		Direct - Financial	Funding to nominating organisation PBC Foundation from Gilead 2024 financials within last 12 months £20,000 - Bronze corporate sponsorship £4,000 - Argentina Conference £40,000 - Translation website £35,000 - Summit 2025 £5,000 - Online Drs Pulse module £300 - PFIS patient narrative consulting fees (completed) £700 - EASL PAG meeting consulting fees £150000 - Patient Conference sponsorship (committed in December 2024, paid in 2025)	10/09/2025	

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			£800 - Doctors.net modules £1000 - PBC medical education meeting		
			My organisation has received: Gilead £20,000 – Sponsorship Patient Conference £800 – June - staff consultancy fee £300 – BASL - staff consultancy fee Ipsen £5000 – online GP Module £40,000 – sponsorship of PBC International Summit £40,000 – Corporate sponsorship – Gold £20,000 - Sponsorship Patient Conference £524 – May staff consultancy fee £980 - May staff consultancy fee £1700 – June staff consultancy fee £980 – Dec - staff consultancy fee Advanz £35,000 – sponsorship of PBC International £15,000 – Sponsorship Patient Conference £40,000 – Core funding Intercept	23/02/2026	

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			£35,000 – sponsorship of PBC International Summit £65,000 – Corporate sponsorship – Sapphire £15,000 - Sponsorship Patient Conference £58,000 – USA project – online services		
Yun Jung Kim	Expert	Direct – Financial	Dr Falk – Advisory fees & IPSEN – speaker fees (expected in April 2026)	05/02/2026	It was agreed that Yun’s declaration would not prevent them from providing expert advice to the committee.
		Financial	BHPG received sponsorship from the following companies to run our annual educational event. • Ipsen • Madrigal • Univar • Norgine • Dr Falk • Gilead	06/05/2026	